

12th World Congress of the International Photodynamic Association

Photodynamic Therapy: Back to the Future

David H. Kessel
Editor

11–15 June 2009
Seattle, Washington, United States

Organized by
SPIE

Sponsored by
Air Force Office of Scientific Research (United States)
Axcan Pharma Inc. (United States)
Covidien Imaging Solutions (United States)
IPA—International Photodynamic Association
Ondine Biopharma Corporation (Canada)
Photocure ASA (Norway)
QinetiQ North America
Wellman Center for Photomedicine (United States)
Wayne State University (United States)

Published by
SPIE

Volume 7380

Proceedings of SPIE, 1605-7422, v. 7380

SPIE is an international society advancing an interdisciplinary approach to the science and application of light.

The papers included in this volume were part of the technical conference cited on the cover and title page. Papers were selected and subject to review by the editors and conference program committee. Some conference presentations may not be available for publication. The papers published in these proceedings reflect the work and thoughts of the authors and are published herein as submitted. The publisher is not responsible for the validity of the information or for any outcomes resulting from reliance thereon.

Please use the following format to cite material from this book:

Author(s), "Title of Paper," in *Photodynamic Therapy: Back to the Future*, edited by David H. Kessel, Proceedings of SPIE Vol. 7380 (SPIE, Bellingham, WA, 2009) Article CID Number.

ISSN 1605-7422

ISBN 9780819476609

Published by

SPIE

P.O. Box 10, Bellingham, Washington 98227-0010 USA

Telephone +1 360 676 3290 (Pacific Time) · Fax +1 360 647 1445

SPIE.org

Copyright © 2009, Society of Photo-Optical Instrumentation Engineers.

Copying of material in this book for internal or personal use, or for the internal or personal use of specific clients, beyond the fair use provisions granted by the U.S. Copyright Law is authorized by SPIE subject to payment of copying fees. The Transactional Reporting Service base fee for this volume is \$18.00 per article (or portion thereof), which should be paid directly to the Copyright Clearance Center (CCC), 222 Rosewood Drive, Danvers, MA 01923. Payment may also be made electronically through CCC Online at copyright.com. Other copying for republication, resale, advertising or promotion, or any form of systematic or multiple reproduction of any material in this book is prohibited except with permission in writing from the publisher. The CCC fee code is 1605-7422/09/\$18.00.

Printed in the United States of America.

Publication of record for individual papers is online in the SPIE Digital Library.

SPIE 
Digital Library

SPIDigitalLibrary.org

Paper Numbering: Proceedings of SPIE follow an e-First publication model, with papers published first online and then in print and on CD-ROM. Papers are published as they are submitted and meet publication criteria. A unique, consistent, permanent citation identifier (CID) number is assigned to each article at the time of the first publication. Utilization of CIDs allows articles to be fully citable as soon they are published online, and connects the same identifier to all online, print, and electronic versions of the publication. SPIE uses a six-digit CID article numbering system in which:

- The first four digits correspond to the SPIE volume number.
- The last two digits indicate publication order within the volume using a Base 36 numbering system employing both numerals and letters. These two-number sets start with 00, 01, 02, 03, 04, 05, 06, 07, 08, 09, 0A, 0B ... 0Z, followed by 10-1Z, 20-2Z, etc.

The CID number appears on each page of the manuscript. The complete citation is used on the first page, and an abbreviated version on subsequent pages. Numbers in the index correspond to the last two digits of the six-digit CID number.

Contents

xix *Conference Committee*

Part One

PLENARY PAPERS

- 7380 05 **Taking PDT into mainstream clinical practice (Plenary Paper)** [7380-304]
S. G. Bown, Univ. College London (United Kingdom)
- 7380 07 **Photodynamic application in neurosurgery: present and future (Plenary Paper)** [7380-306]
H. Kostron, Medical Univ. Innsbruck (Austria)

PDT MECHANISMS OF PHOTOTOXICITY

- 7380 08 **Identifying initial molecular targets of PDT: protein and lipid oxidation products** [7380-01]
N. L. Oleinick, J. Kim, M. E. Rodriguez, L. Xue, M. E. Kenney, V. E. Anderson, Case Western Reserve Univ. (United States)
- 7380 09 **Photodynamic therapy: first responses** [7380-02]
D. Kessel, M. Price, Wayne State Univ. (United States)
- 7380 0C **Signaling from lysosomes enhances mitochondria-mediated photodynamic therapy in cancer cells** [7380-196]
G. Quiogue, S. Saggi, H.-I Hung, Medical Univ. of South Carolina (United States);
M. E. Kenney, N. L. Oleinick, Case Western Reserve Univ. (United States); J. J. Lemasters,
A.-L. Nieminen, Medical Univ. of South Carolina (United States)

PDT AND IMMUNE RESPONSES I

- 7380 0F **Anti-tumor immune response after photodynamic therapy** [7380-07]
P. Mroz, A. P. Castano, Wellman Ctr. for Photomedicine, MGH (United States) and Harvard Medical School (United States); M. X. Wu, Wellman Ctr. for Photomedicine, MGH (United States), Harvard Medical School (United States), and Harvard-MIT Division of Health Sciences and Technology (United States); A. L. Kung, Dana-Farber Cancer Institute (United States); M. R. Hamblin, Wellman Ctr. for Photomedicine, MGH (United States), Harvard Medical School (United States), and Harvard-MIT Division of Health Sciences and Technology (United States)

- 7380 OH **Combination of PDT and a DNA demethylating agent produces anti-tumor immune response in a mouse tumor model** [7380-09]
P. Mroz, Wellman Ctr. for Photomedicine, MGH (United States) and Harvard Medical School (United States); M. R. Hamblin, Wellman Ctr. for Photomedicine, MGH (United States), Harvard Medical School (United States), and Harvard-MIT Division of Health Sciences and Technology (United States)

PDT: SOME OF THE VARIABLES

- 7380 OL **Intravital fiber-optic fluorescence imaging for monitoring ovarian carcinoma progression and treatment response** [7380-248]
B. Q. Spring, J. P. Celli, C. L. Evans, W. Zhong, I. Rizvi, Z. Mai, Wellman Ctr. for Photomedicine, MGH (United States); J. Mertz, Boston Univ. (United States); S. H. Yun, T. Hasan, Wellman Ctr. for Photomedicine, MGH (United States)
- 7380 ON **Variables in photodynamic therapy for Barrett's esophagus** [7380-16]
L. R. Jones, N. W. Preyer, J. Buchanan, D. M. Reynolds, College of Charleston (United States); H. C. Wolfsen, M. B. Wallace, K. R. S. Gill, Mayo Clinic (United States)
- 7380 OO **Photoreactions for total antioxidant status measurement in humans** [7380-17]
D. Olivier, S. Douillard, I. Lhommeau, E. Bigot, T. Patrice, Hôpital Laënnec (France)

CLINICAL PDT I

- 7380 OP **Efficacy of low-dose mTHPC-PDT for the treatment of basal cell carcinomas** [7380-19]
C. S. Betz, Ludwig Maximilian Univ. Munich (Germany) and Univ. College London (United Kingdom); W. Rauschnig, Biolitec Pharma Ltd. (Ireland); E. P. Stranadko, M. V. Riabov, Russian Ministry of Public Health (Russian Federation); V. Albrecht, N. E. Nifantiev, Biolitec AG (Germany); C. Hopper, Ludwig Maximilian Univ. Munich (Germany) and Univ. College London (United Kingdom)

CLINICAL PDT II

- 7380 OU **Which intracranial lesions would be suitable for fluoresce guided resection?: A prospective review of 110 consecutive lesions** [7380-24]
M. S. Eljamel, Ninewells Hospital and Medical School, Univ. of Dundee (United Kingdom)
- 7380 OV **Palliative photodynamic therapy for biliary tract carcinoma may improve survival and has a similar outcome to attempted curative surgery with positive resection margins** [7380-25]
S. P. Pereira, W. R. Matull, D. K. Dhar, L. Ayaru, N. S. Sandanayake, M. H. Chapman, Univ. College London (United Kingdom)
- 7380 OW **Nanotechnology-based combination therapy improves treatment response in cancer models** [7380-26]
P. Rai, S. K. Chang, Z. Mai, D. Neuman, T. Hasan, Wellman Ctr. for Photomedicine, MGH (United States)

PHOTOCURE WORKSHOP ON PDT AND PD WITH PORPHYRIN PRECURSORS

- 7380 0X **Apoptotic induction by photodynamic therapy using hexaminolevulinate with a literature review** [7380-27]
I. E. Furre, J. M. Nesland, Q. Peng, Rikshospitalet Univ. Hospital (Norway)
- 7380 0Z **Novel multifunctional acyloxyalkyl ester prodrugs of 5-aminolevulinic acid display improved anticancer activity dependent on photoactivation** [7380-29]
G. Berkovitch, A. Nudelman, B. Ehenberg, Bar Ilan Univ. (Israel); A. Rephaeli, Tel-Aviv Univ. (Israel); Z. Malik, Bar Ilan Univ. (Israel)
- 7380 10 **Enhancing protoporphyrin IX-induced PDT** [7380-30]
A. Curnow, A. Pye, S. Campbell, Peninsula Medical School (United Kingdom)
- 7380 11 **The effect of ALA/PpIX PDT on putative cancer stem cells in tumor side populations** [7380-31]
J. Morgan, C. M. Petrucci, Roswell Park Cancer Institute (United States)

WORKSHOP II

- 7380 13 **Novel drug delivery strategies for porphyrins and porphyrin precursors** [7380-33]
D. I. J. Morrow, R. F. Donnelly, Queen's Univ. Belfast (United Kingdom)

WORKSHOP III

- 7380 18 **ALA PDT for high grade dysplasia in Barrett's oesophagus: review of a decade's experience** [7380-38]
S. G. Bown, G. D. Mackenzie, J. M. Dunn, S. M. Thorpe, L. B. Lovat, Univ. College London (United Kingdom) and Univ. College London Hospitals (United Kingdom)

WORKSHOP IV

- 7380 1C **Targeted opening of the blood brain barrier by ALA-mediated photodynamic therapy** [7380-43]
H. Hirschberg, Beckman Laser Institute, Univ. of California, Irvine (United States) and Univ. of Nevada, Las Vegas (United States); Q. Peng, The Norwegian Radium Hospital, Rikshospitalet Univ. Hospital (Norway); F. A. Uzal, Univ. of California, Davis (United States); D. Chighvinadze, M. J. Zhang, S. J. Madsen, Univ. of Nevada, Las Vegas (United States)
- 7380 1D **ALA-mediated fluorescence-guided resection (FGR) and PDT of glioma** [7380-44]
A. Johansson, H. Stepp, T. Beck, W. Beyer, T. Pongratz, R. Sroka, Univ. Clinic Munich (Germany); T. Meinel, clinstud GmbH (Germany); W. Stummer, Univ. of Düsseldorf (Germany); F.-W. Kreth, J.-C. Tonn, R. Baumgartner, Univ. Clinic Munich (Germany)

PRECLINICAL I

- 7380 1I **Novel PDD-PDT system based on spectrophotometric real-time fluorescence monitoring and MALDI-TOF-MS analysis of tumors** [7380-50]
T. O. Yoshida, E. Kohno, M. Dodeller, T. Sakurai, S. Yamamoto, S. Terakawa, Hamamatsu Univ. School of Medicine (Japan)

CLINICAL PDT III

- 7380 1M **In-vivo fluorescence dosimetry of aminolevulinic acid-based protoporphyrin IX (PpIX) accumulation in human nonmelanoma skin cancers and precancers** [7380-54]
C. B. Warren, S. Lohser, Cleveland Clinic Lerner Research Institute (United States); S. Chang, Wellman Ctr. for Photomedicine, MGH (United States) and Harvard Medical School (United States); P. A. Bailin, E. V. Maytin, Cleveland Clinic Lerner Research Institute (United States)
- 7380 1O **New pain-relieving strategies for topical photodynamic therapy** [7380-68]
C. B. Halldin, J. Paoli, C. Sandberg, M. B. Ericson, H. Gonzalez, A.-M. Wennberg, Sahlgrenska Univ. Hospital-Univ. of Gothenburg (Sweden)
- 7380 1P **The utilization of a non-invasive fluorescence imaging system to follow clinical dermatological MAL-PDT** [7380-57]
J. Tyrrell, S. Campbell, A. Curnow, Peninsula Medical School (United Kingdom)

CLINICAL PDT IV

- 7380 1R **Low dose Photofrin PDT for recurrent in-situ squamous cell tumors of the head and neck** [7380-59]
R. R. Allison, C. Austerlitz, C. Sheng, H. Mota, B. Brodish, P. Camnitz, C. H. Sibata, Brody School of Medicine at East Carolina Univ. (United States)
- 7380 1S **Photodynamic management of bladder cancer** [7380-60]
A. Johansson, H. Stepp, W. Beyer, T. Pongratz, R. Sroka, M. Bader, Univ. Clinic Munich (Germany); M. Kriegmair, Urology Clinic Dr. Castringius Munich-Planegg (Germany); D. Zaak, Urology Clinic Traunstein (Germany); R. Waidelich, A. Karl, A. Hofstetter, C. Stief, R. Baumgartner, Univ. Clinic Munich (Germany)
- 7380 1V **Prevention of bladder tumor implantation after fluorescence-guided TUR with photodynamic therapy** [7380-63]
S. Berrahmoune, L. Bezdetnaya, Ctr. de Recherche en Automatique de Nancy, Nancy Univ., CNRS, Ctr. Alexis Vautrin (France); P. de Witte, Katholieke Univ. Leuven (Belgium); A. Leroux, Ctr. de Recherche en Automatique de Nancy, Nancy Univ., CNRS, Ctr. Alexis Vautrin (France); D. Dumas, Nancy Univ., CNRS (France); F. Guillemain, M. A. D'Hallewin, Ctr. de Recherche en Automatique de Nancy, Nancy Univ., CNRS, Ctr. Alexis Vautrin (France)

CLINICAL PDT V

- 7380 1W **A light blanket for intraoperative photodynamic therapy** [7380-64]
Y. Hu, K. Wang, T. C. Zhu, Univ. of Pennsylvania (United States)
- 7380 1Y **Preliminary study of verteporfin photodynamic therapy in a canine prostate model**
[7380-66]
Z. Huang, F. Hetzel, K. Dole, D. Luck, J. Beckers, HealthONE Alliance (United States); D. Maul,
Pre-Clinical Research Services, Inc. (United States)
- 7380 1Z **Topical application of ALA PDT for the treatment of moderate to severe acne vulgaris**
[7380-67]
X.-L. Wang, H.-W. Wang, L.-L. Zhang, L. Su, M.-X. Guo, Z. Huang, Shanghai Skin Diseases and
STD Hospital (China)

PDT MECHANISMS

- 7380 26 **Using iron chelating agents to enhance dermatological PDT** [7380-75]
A. Curnow, Peninsula Medical School, Royal Cornwall Hospital (United Kingdom); Y. Dogra,
P. Winyard, S. Campbell, Peninsula Medical School (United Kingdom)
- 7380 27 **Novel type 1 photosensitizers: viability of leukemia cells exposed to reactive intermediates
generated in situ by in vitro photofragmentation** [7380-76]
R. Rajagopalan, A. Karwa, P. M. Lusiak, K. Srivastava, A. R. Poreddy, R. S. Pandurangi,
K. P. Galen, Covidien Imaging Solutions (United States); W. L. Neumann, Southern Illinois Univ.
(United States); G. E. Cantrell, R. B. Dorshow, Covidien Imaging Solutions (United States)
- 7380 29 **The correlation between photosensitizers' membrane localization, membrane-residing
targets, and photosensitization efficiency** [7380-78]
S. Ytzhak, S. Bernstein, Bar Ilan Univ. (Israel); L. M. Loew, Univ. of Connecticut Health Ctr.
(United States); B. Ehrenberg, Bar Ilan Univ. (Israel)

PDT TECHNIQUES

- 7380 2A **Introduction of an ultrathin and flexible laser scanning endoscope for color imaging and
integrated PDD and future PDT** [7380-79]
E. J. Seibel, H. L. Kenerson, C. M. Lee, C. D. Melville, R. S. Johnston, R. S. Yeung, Univ. of
Washington (United States)

SENSITIZER SYNTHESIS I

- 7380 2H **Beta-lactamase targeted enzyme activatable photosensitizers for antimicrobial PDT**
[7380-86]
X. Zheng, S. Verma, U. W. Sallum, T. Hasan, Wellman Ctr. for Photomedicine, MGH (United
States) and Harvard Medical School (United States)

SENSITIZER SYNTHESIS II

- 7380 2K **New porphyrin glyco-conjugates** [7380-89]
C. M. Drain, Hunter College of CUNY (United States) and The Rockefeller Univ. (United States); S. Singh, D. Samaroo, S. Thompson, M. Vinodu, J. P. C. Tome, Hunter College of CUNY (United States)

PDT BIOPHYSICS AND NANOTECH

- 7380 2P **Photodynamic synchrotron x-ray therapy in glioma cell using superparamagnetic iron nanoparticle** [7380-94]
H.-T. Kim, Catholic Univ. of Taegu (Korea, Republic of); K.-H. Kim, Kyungwoon Univ. (Korea, Republic of); G.-H. Choi, Catholic Univ. of Taegu (Korea, Republic of); S. Jheon, Seoul National Univ. Bundang Hospital (Korea, Republic of); S.-H. Park, B.-I. Kim, Catholic Univ. of Taegu (Korea, Republic of); K. Hyodo, KEK (Japan); M. Ando, Tokyo Univ. of Science (Japan); J.-K. Kim, Catholic Univ. of Taegu (Korea, Republic of)

CLINICAL PDT VI

- 7380 2Q **Clearance of protoporphyrin IX induced by 5-aminolevulinic acid from WiDr human colon carcinoma cells** [7380-95]
A. Juzeniene, Oslo Univ. Hospital (Norway); M. Kaliszewski, Oslo Univ. Hospital (Norway) and Military Univ. of Technology (Poland); A. Bugaj, Oslo Univ. Hospital (Norway); J. Moan, Oslo Univ. Hospital (Norway) and Univ. of Oslo (Norway)
- 7380 2S **New stable synthetic bacteriochlorins for photodynamic therapy of melanoma** [7380-97]
P. Mroz, Y.-Y. Huang, Wellman Ctr. for Photomedicine, MGH (United States) and Harvard Medical School (United States); S. Janjua, Wellman Ctr. for Photomedicine, MGH (United States) and Aga Khan Medical College (Pakistan); T. Zhiyentayev, Wellman Ctr. for Photomedicine, MGH (United States) and M.V. Lomonosov Moscow State Univ. (Russian Federation); C. Ruzié, K. E. Borbas, D. Fan, M. Krayner, North Carolina State Univ. (United States); T. Balasubramanian, NIRvana Pharmaceuticals, Inc. (United States); E. K. Yang, H. L. Kee, D. Holten, Washington Univ. in St. Louis (United States); J. S. Lindsey, North Carolina State Univ. (United States); M. R. Hamblin, Wellman Ctr. for Photomedicine, MGH (United States), Harvard Medical School (United States), and Harvard-MIT Division of Health Sciences and Technology (United States)
- 7380 2T **Selenium enhances the efficacy of Radachlorin-mediated photodynamic therapy in cervical cancer model** [7380-216]
D. H. Bae, Soonchunhyang Univ. (Korea, Republic of); L. Y. Wen, S. M. Bae, The Catholic Univ. of Korea (Korea, Republic of); U. Kang, K. H. Kim, Korea Electrotechnology Research Institute (Korea, Republic of); S. H. Jheon, J. S. Lee, Seoul National Univ. Hospital (Korea, Republic of); W. S. Ahn, The Catholic Univ. of Korea (Korea, Republic of)

CLINICAL PDT VII

- 7380 2V **Combination of PDT and topical angiogenic inhibitor for treatment of port wine stain (PWS) birthmarks: a novel approach** [7380-100]
K. Yuan, General Hospital of Guangzhou Military Command (China); Q. Huang, Southern Medical Univ. (China); Z. Huang, Univ. of Colorado at Denver (United States)
- 7380 2Y **A pilot study comparing the pain sensations during PpIX build-up and clearance phases** [7380-104]
P. Mikolajewska, A. Juzeniene, V. Iani, Norwegian Radium Hospital, Rikshospitalet Univ. Hospital (Norway); H. Sollund, Univ. of Oslo (Norway); G. Norsang, Tibet Univ. (China); J. Moan, Norwegian Radium Hospital, Rikshospitalet Univ. Hospital (Norway) and Tibet Univ. (China)

CLINICAL PDT VIII

- 7380 2Z **Results of combined photodynamic therapy (PDT) and high dose rate brachytherapy (HDR) in treatment of obstructive endobronchial non-small cell lung cancer** [7380-105]
B. D. Weinberg, R. R. Allison, C. Sibata, T. Parent, G. Downie, Brody School of Medicine at East Carolina Univ. (United States)
- 7380 31 **Photodynamic therapy of cervical intraepithelial neoplasia using hexaminolevulinate and methylaminolevulinate** [7380-107]
P. Soergel, I. Staboulidou, H. Hertel, C. Schippert, P. Hillemanns, Hannover Medical School (Germany)
- 7380 32 **Combination of vascular targeting PDT with combretastatin A4 phosphate** [7380-108]
C. He, B. Fateye, B. Chen, Univ. of the Sciences in Philadelphia (United States)
- 7380 33 **HAL fluorescence cystoscopy: towards a new paradigm in bladder cancer management** [7380-162]
P. Jichlinski, CHUV Univ. Hospital (Switzerland)

ANTIMICROBIAL PDT II

- 7380 37 **Antimicrobial photodynamic therapy in a mouse model of *Acinetobacter baumannii* burn infection** [7380-113]
T. Dai, G. P. Tegos, Wellman Ctr. for Photomedicine, MGH (United States) and Harvard Medical School (United States); Z. Lu, Wellman Ctr. for Photomedicine, MGH (United States) and Tianjin Medical Univ. (China); T. Zhiyentayev, Wellman Ctr. for Photomedicine, MGH (United States) and M.V. Lomonosov Moscow State Univ. (Russian Federation); L. Huang, Wellman Ctr. for Photomedicine, MGH (United States), Harvard Medical School (United States), and Guangxi Medical Univ. (China); M. J. Franklin, Montana State Univ. (United States); D. G. Baer, US Army Institute of Surgical Research (United States); M. R. Hamblin, Wellman Ctr. for Photomedicine, MGH (United States), Harvard Medical School (United States), and Harvard-MIT Division of Health Sciences and Technology (United States)

- 7380 39 **Investigation into the susceptibility of *Burkholderia cepacia* complex isolates to photodynamic antimicrobial chemotherapy (PACT)** [7380-115]
C. M. Cassidy, A. L. Watters, R. F. Donnelly, M. M. Tunney, Queen's Univ. Belfast (United Kingdom)
- 7380 3B **Antimicrobial photodynamic therapy for the decolonization of methicillin-resistant *Staphylococcus aureus* from the anterior nares** [7380-117]
C. N. Street, L. Pedigo, A. Gibbs, N. G. Loebel, Ondine Biopharma Corp. (United States)

ANTIMICROBIAL PDT III

- 7380 3D **Influence of bacterial interactions on the susceptibility to photodynamic inactivation** [7380-119]
M. H. Upadya, National Univ. of Singapore (Singapore); G. Tegos, M. Hamblin, Wellman Ctr. for Photomedicine, MGH (United States); A. Kishen, National Univ. of Singapore (Singapore)
- 7380 3E **Photodynamic dosimetry in the treatment of periodontitis** [7380-120]
R. C. Andersen, N. G. Loebel, Ondine Biopharma Corp. (United States); D. M. Andersen, Loma Linda Univ. (United States)
- 7380 3F **Photodynamic inactivation of antibiotic resistant strain of *Pseudomonas aeruginosa* in vivo** [7380-121]
M. C. E. Hashimoto, D. J. Toffoli, R. A. Prates, Instituto de Pesquisas Energéticas e Nucleares (Brazil); L. C. Courrol, Instituto de Pesquisas Energéticas e Nucleares (Brazil) and Unifesp (Brazil); M. S. Ribeiro, Instituto de Pesquisas Energéticas e Nucleares (Brazil)
- 7380 3G **Photochemistry-based immune modulation in the treatment of cutaneous leishmaniasis** [7380-122]
O. E. Akilov, S. Kosaka, T. Hasan, Wellman Center for Photomedicine, MGH (United States) and Harvard Medical School (United States)

ANTIMICROBIAL PDT IV

- 7380 3H **Absence of bacterial resistance following repeat exposure to photodynamic therapy** [7380-123]
L. A. Pedigo, A. J. Gibbs, R. J. Scott, C. N. Street, Ondine Biopharma Corp. (United States)
- 7380 3I **Photodynamic inactivation of Gram (-) and Gram (+) microorganisms by cationic porphyrins and metalloporphyrins** [7380-124]
G. V. Gyulkhandanyan, M. H. Paronyan, A. S. Hovsepyan, Institute of Biotechnology (Armenia); R. K. Ghazaryan, A. G. Tovmasyan, Yerevan State Medical Univ. (Armenia); A. G. Gyulkhandanyan, A. G. Gyulkhandanyan, Yerevan State Univ. (Armenia); G. V. Amelyan, Institute of Biotechnology (Armenia)
- 7380 3J **Strategies for targeted antimicrobial photodynamic therapy** [7380-125]
S. Verma, U. Sallum, X. Zheng, T. Hasan, Wellman Ctr. for Photomedicine, MGH (United States) and Harvard Medical School (United States)

PDT DOSIMETRY

- 7380 3M **A study of MRI-guided diffuse fluorescence molecular tomography for monitoring PDT effects in pancreas cancer** [7380-127]
K. S. Samkoe, S. C. Davis, S. Srinivasan, J. A. O'Hara, Dartmouth College (United States); T. Hasan, Wellman Ctr. for Photomedicine, MGH (United States); B. W. Pogue, Dartmouth College (United States) and Wellman Ctr. for Photomedicine, MGH (United States)

Part Two

PDT EVALUATION TECHNIQUES

- 7380 3P **Photofrin-PDT for gastric cancer in the era of endoscopic submucosal dissection** [7380-130]
Y. Nishiwaki, Y. Ikematsu, Y. Tokunaga, T. Kanai, Hamamatsu Medical Ctr. (Japan)
- 7380 3Q **Correction of fluorescence for depth-specific optical and vascular properties using reflectance and differential path-length spectroscopy during PDT** [7380-131]
F. van Zaane, T. A. Middelburg, H. S. de Bruijn, A. van der Ploeg-van den Heuvel, E. R. M. de Haas, H. J. C. M. Sterenborg, H. A. M. Neumann, D. J. Robinson, Erasmus Medical Ctr. (Netherlands)
- 7380 3S **Islands of surviving cells within necrotic volume at liver induced by PDT** [7380-133]
J. Ferreira, C. Kurachi, S. Zucoloto, O. Castro e Silva, Jr., V. S. Bagnato, Univ. de São Paulo (Brazil)

PDT NEW APPROACHES

- 7380 3W **Vascular effects induced by anti-VEGF agents in the CAM model: effect of the DMSO** [7380-137]
P. Nowak-Sliwinska, J.-P. Ballini, H. van den Bergh, G. Wagnières, Swiss Federal Institute of Technology (Switzerland)

PDT TARGETING

- 7380 3Y **PDT-induced in vitro bystander effect** [7380-139]
D. Olivier, S. Douillard, T. Patrice, Hôpital Laënnec (France)
- 7380 3Z **Targeted two-photon PDT photo-sensitizers for the treatment of subcutaneous tumors** [7380-140]
C. W. Spangler, Rasiris, Inc. (United States); A. Rebane, J. Starkey, M. Drobizhev, Montana State Univ. (United States)

- 7380 40 **Evaluation of toxicological properties and photodynamic activity of Photolon ointment: an experimental study** [7380-141]
S. V. Shliakhtsin, T. V. Trukhachova, RUE Belmedpreparaty (Belarus); Y. P. Istomin, N.N. Alexandrov National Cancer Ctr. of Belarus (Belarus); L. N. Dunetz, RUE Belmedpreparaty (Belarus); A. V. Kuvshinov, S. A. Naumovich, Byelorussian State Medical Univ. (Belarus)
- 7380 41 **Anti-tumor effects on the combination of photodynamic therapy with arsenic compound in TC-1 cells implanted C57BL/6 mice** [7380-142]
K. W. Lee, Korea Univ. (Korea, Republic of); L. Y. Wen, S. M. Bae, The Catholic Univ. of Korea (Korea, Republic of); C. H. Park, Dankook Univ. (Korea, Republic of); W. K. Jeon, Samsung Medical Ctr. (Korea, Republic of); D. Y. Lee, Yonsei Univ. (Korea, Republic of); W. S. Ahn, The Catholic Univ. of Korea (Korea, Republic of)
- 7380 42 **Endoscopic treatment of early bronchial cancer: our experience with photodynamic therapy (PDT)** [7380-270]
L. Corti, Univ. of Padua (Italy); L. Toniolo, City Hospital (Italy); C. Boso, Univ. of Padua (Italy); F. Colaut, City Hospital (Italy); D. Fiore, P.-C. Muzzio, L. Loreggian, G. Sotti, Univ. of Padua (Italy)

PDT BIOPHYSICS I

- 7380 44 **Reconstruction of hemodynamics and sensitizer distributions during interstitial PDT using spectroscopy with linear light sources** [7380-144]
J. C. Finlay, K. Wang, Y. Hu, T. C. Zhu, Univ. of Pennsylvania (United States)
- 7380 45 **Singlet oxygen kinetics inside living cells: observation of endogenous quencher consumption and consequences for the spatial resolution in time-resolved measurements** [7380-145]
S. Hackbarth, J. Schlothauer, A. Preuß, B. Röder, Humboldt-Univ. zu Berlin (Germany)

PDT BIOPHYSICS II

- 7380 46 **A singlet oxygen monitor as an in vivo photodynamic therapy dosimeter** [7380-146]
S. Lee, K. Galbally-Kinney, M. F. Hinds, Physical Sciences Inc. (United States); J. A. O'Hara, B. W. Pogue, Dartmouth-Hitchcock Medical Ctr. (United States); A. Liang, T. Hasan, Wellman Ctr. for Photomedicine, MGH (United States); S. J. Davis, Physical Sciences Inc. (United States)
- 7380 47 **Bladder cancer detection by fluorescence imaging with Hexvix: analysis and processing of images obtained during high magnification cystoscopy** [7380-147]
B. Lovisa, Swiss Federal Institute of Technology (Switzerland); P. Jichlinski, D. Aymon, CHUV Univ. Hospital (Switzerland); B.-C. Weber, Richard Wolf GmbH (Germany); H. van den Bergh, G. Wagnières, Swiss Federal Institute of Technology (Switzerland)
- 7380 48 **Hyperspectral two-photon near-infrared cancer imaging at depth** [7380-148]
N. S. Makarov, J. Starkey, M. Drobizhev, Montana State Univ. (United States); A. Rebane, Montana State Univ. (United States) and National Institute of Chemical Physics and Biophysics (Estonia)

- 7380 49 **The design of a robotic multichannel platform for photodynamic therapy** [7380-149]
Y. Hu, J. C. Finlay, T. C. Zhu, Univ. of Pennsylvania (United States)

PRECLINICAL PDT METHODOLOGY I

- 7380 4B **Enhancement of tumor responsiveness to aminolevulinic-acid-photodynamic therapy (ALA-PDT) using differentiation-promoting agents in mouse models of skin carcinoma** [7380-152]
S. Anand, G. Honari, A. Paliwal, Cleveland Clinic (United States); T. Hasan, Wellman Ctr. for Photomedicine, MGH (United States) and Harvard Medical School (United States); E. V. Maytin, Cleveland Clinic (United States) and Wellman Ctr. for Photomedicine, MGH (United States) and Harvard Medical School (United States)

PRECLINICAL PDT METHODOLOGY II

- 7380 4F **Improvement of anti-tumor activity of photodynamic therapy through inhibition of cytoprotective mechanism in tumor cells** [7380-156]
D. Nowis, A. Szokalska, M. Makowski, M. Winiarska, J. Golab, Medical Univ. of Warsaw (Poland)
- 7380 4G **Comparison of ATP level in U937 cells in vitro using two different photosensitizers in photodynamic therapy** [7380-157]
N. Nakajima, N. Kawashima, Toin Univ. of Yokohama (Japan)
- 7380 4H **Comparison of aminolevulinic acid and hexylester aminolevulinic acid induced protoporphyrin IX fluorescence for the detection of ovarian carcinoma metastases: an experimental study** [7380-158]
M. Ascencio, C. Regis, Lille Univ. Hospital (France); S. Mordon, INSERM, Lille Univ. Hospital (France); P. Collinet, Lille Univ. Hospital (France)
- 7380 4I **Light fractionation increases the efficacy of ALA-PDT but not of MAL-PDT: What is the role of (vascular) endothelial cells?** [7380-159]
H. S. de Bruijn, H. C. de Vrijlder, E. R. M. de Haas, A. van der Ploeg-van den Heuvel, B. Kruijt, D. Poel-Dirks, H. J. C. M. Sterenborg, T. L. M. ten Hagen, D. J. Robinson, Erasmus Medical Ctr. (Netherlands)

POSTER SESSION

- 7380 4J **Burn, freeze, or photo-ablate?: comparative symptom profile in Barrett's dysplasia patients undergoing endoscopic ablation** [7380-110]
K. R. S. Gill, Mayo Clinic (United States); S. A. Gross, Norwalk Hospital (United States); B. D. Greenwald, Univ. of Maryland School of Medicine (United States); L. L. Hemminger, H. C. Wolfsen, Mayo Clinic (United States)
- 7380 4K **Meta-analysis of five photodisinfection clinical trials for periodontitis** [7380-260]
R. C. Andersen, N. G. Loebel, Ondine Research Labs., Inc. (United States); D. M. Andersen, Loma Linda Univ. (United States)

- 7380 4L **Short and long term stability of the Diomed 630PDT laser evaluated with integrating sphere, power meter, and calorimeter** [7380-164]
C. Austerlitz, D. Campos, R. Allison, C. Sheng, C. Bonnerup, C. Sibata, East Carolina Univ. (United States)
- 7380 4O **Investigation into the potential of sub-lethal photodynamic antimicrobial chemotherapy (PACT) to reduce susceptibility of meticillin-resistant *Staphylococcus aureus* (MRSA) to antibiotics** [7380-167]
C. M. Cassidy, R. F. Donnelly, M. M. Tunney, Queen's Univ. Belfast (United Kingdom)
- 7380 4R **Synthesis and cellular localization of porphyrinic pigments** [7380-171]
S. Sareh, S. Kong, L. Parrales, A. Jung, K. Cross, San Francisco State Univ. (United States); B. Röder, Humboldt-Univ. zu Berlin (Germany); M. Isaac, U. Simonis, San Francisco State Univ. (United States)
- 7380 4V **Effects of vascular targeting photodynamic therapy on lymphatic tumor metastasis** [7380-175]
B. Fateye, C. He, B. Chen, Univ. of the Sciences in Philadelphia (United States)
- 7380 4Y **In vitro and in vivo evaluation of the induced PDT response using a femtosecond laser** [7380-178]
C. Grecco, C. Kurachi, V. S. Bagnato, Univ. of São Paulo (Brazil)
- 7380 51 **The new application of photosensitization reaction to atrial fibrillation treatment: mechanism and demonstration of non-thermal electrical conduction block with porcine heart** [7380-182]
A. Ito, H. Matsuo, T. Suenari, T. Kajihara, Keio Univ. (Japan); T. Kimura, S. Miyoshi, S. Ogawa, Keio Univ. School of Medicine (Japan); T. Arai, Keio Univ. (Japan)
- 7380 54 **Treatment of vulvar/vaginal condyloma by HPV: developed instrumentation and clinical report** [7380-185]
N. M. Inada, C. Kurachi, J. Ferreira, E. S. Ribeiro, O. C. C. Guimarães, S. M. Quintana, Univ. de São Paulo (Brazil); W. Lombardi, UNIARA (Brazil); V. S. Bagnato, Univ. de São Paulo (Brazil)
- 7380 5A **Design and evaluation of excitation light source device for fluorescence endoscope** [7380-191]
H. S. Lim, Chungnam National Univ. (Korea, Republic of)
- 7380 5B **Fluorescence diagnosis in tissue injury** [7380-192]
V. H. Maciel, J. Ferreira, V. S. Bagnato, Univ. de São Paulo (Brazil)
- 7380 5D **Novel non-thermal atrial fibrillation treatment with photosensitization reaction: possibility of permanent electrical blockade in rat chronic model** [7380-194]
H. Matsuo, A. Ito, Keio Univ. (Japan); S. Miyoshi, K. Soejima, S. Ogawa, Keio Univ. School of Medicine (Japan); T. Arai, Keio Univ. (Japan)

- 7380 5F **Uptake of verteporfin by orthotopic xenograft pancreas models with different levels of aggression** [7380-197]
J. O'Hara, K. S. Samkoe, A. Chen, Dartmouth College (United States); P. J. Hoopes, Dartmouth Medical School (United States); I. Rizvi, Dartmouth College (United States) and Wellman Ctr. for Photomedicine, MGH (United States); T. Hasan, Wellman Ctr. for Photomedicine, MGH (United States); B. W. Pogue, Dartmouth College (United States) and Wellman Ctr. for Photomedicine, MGH (United States)
- 7380 5G **Development of a widefield reflectance and fluorescence imaging device for the detection of skin and oral cancer (Best Poster Award)** [7380-199]
S. Pratavieira, P. L. A. Santos, V. S. Bagnato, C. Kurachi, Univ. of São Paulo (Brazil)
- 7380 5H **Multifunctional ORMOSIL and PAA nanoparticles** [7380-200]
A. Gupta, K. V. R. Rao, P. Pera, Roswell Park Cancer Institute (United States); S. J. Wang, Univ. of Michigan (United States); J. R. Missert, Roswell Park Cancer Institute (United States); T. Ohulchansky, I. Roy, SUNY at Buffalo (United States); J. Morgan, Roswell Park Cancer Institute (United States); P. N. Prasad, SUNY at Buffalo (United States); R. Kopelman, Univ. of Michigan (United States); R. K. Pandey, Roswell Park Cancer Institute (United States) and SUNY at Buffalo (United States)
- 7380 5I **Comparative in vivo study of precursors of PpIX (ALA and MAL) used topically in photodynamic therapy** [7380-201]
R. F. Rego, Univ. Federal de São Carlos (Brazil); N. M. Inada, J. Ferreira, Univ. de São Paulo (Brazil); F. M. Araújo-Moreira, Univ. Federal de São Carlos (Brazil); V. S. Bagnato, Univ. de São Paulo (Brazil)
- 7380 5K **Photodynamic therapy for difficult-to-treat basal cell carcinomas: Do poorly responding BCCs lack accumulation of protoporphyrin IX after ALA/MAL application?** [7380-203]
C. Sandberg, J. Paoli, C. B. Halldin, M. Gillstedt, O. Larkö, A.-M. Wennberg, M. B. Ericson, Sahlgrenska Academy, Univ. of Gothenburg (Sweden)
- 7380 5M **Downregulation of the autophagy protein ATG-7 correlates with distinct sphingolipid profile in MCF-7 cells sensitized to photodamage** [7380-205]
D. Separovic, Wayne State Univ. (United States); A. Kelekar, Univ. of Minnesota (United States); A. L. Tarca, Wayne State Univ. (United States); J. Bielawski, Medical Univ. of South Carolina (United States); D. Kessel, Wayne State Univ. (United States)
- 7380 5Q **Synthesis, characterization, and subcellular localization studies of amino acid-substituted porphyrinic pigments** [7380-209]
L. van Diggelen, H. Khin, San Francisco State Univ. (United States); K. Conner, San Francisco State Univ. (United States) and Univ. of Washington (United States); J. Shao, M. Sweezy, A. H. Jung, M. Isaac, U. Simonis, San Francisco State Univ. (United States)
- 7380 5V **Effect of hyperthermia on PDT and imaging** [7380-214]
A. Srivatsan, K. V. R. Rao, Y. Chen, Y. Wang, C. Batt, J. Morgan, A. Sen, E. Repasky, R. K. Pandey, Roswell Park Cancer Institute (United States)

- 7380 5Z **Photodynamic effects of Photodithazine on cervical cancer model** [7380-98]
S. J. Han, Chosun Univ. (Korea, Republic of); L. Y. Wen, S. M. Bae, Y.-S. Hong, H.-S. Jang, The Catholic Univ. of Korea (Korea, Republic of); J. W. Lee, Diotech Korea Co., Ltd. (Korea, Republic of); W. S. Ahn, The Catholic Univ. of Korea (Korea, Republic of)
- 7380 60 **Effectiveness in total reduction of *Candida albicans* promoted by PDT with hypocrellin B:lanthanum** [7380-217]
D. J. Tofolli, R. A. Prates, M. S. Ribeiro, N. D. Vieira, Jr., M. C. E. Hashimoto, Instituto de Pesquisas Energéticas e Nucleares (Brazil); L. C. Courrol, Univ. Federal de São Paulo (Brazil)
- 7380 63 **In vivo quantification of mTHPC fluorescence in skinfold observation chamber using excitation and detection towards the near infrared region** [7380-220]
S. Kascáková, Erasmus Medical Ctr. (Netherlands); S. de Visscher, Univ. Medical Ctr. Groningen (Netherlands); B. Kruijt, H. S. de Bruijn, A. van der Ploeg-van den Heuvel, H. J. C. M. Sterenborg, Erasmus Medical Ctr. (Netherlands); M. J. H. Witjes, Univ. Medical Ctr. Groningen (Netherlands); A. Amelink, Erasmus Medical Ctr. (Netherlands) and Univ. Medical Ctr. Groningen (Netherlands); D. J. Robinson, Erasmus Medical Ctr. (Netherlands)
- 7380 64 **Conjugate systems using delocalized cationic dyes as a carrier of photosensitizers to mitochondria** [7380-221]
Y. You, E. J. Ngen, P. Rajaputra, South Dakota State Univ. (United States)
- 7380 65 **Modulation of COX2 and hTERT expression by photodynamic therapy in human colon cancer cells** [7380-222]
C. L. M. N. Yow, E. S. M. Chu, The Hong Kong Polytechnic Univ. (Hong Kong, China)
- 7380 6A **Fractionated PDT with 5-aminolevulinic acid: effective, cost effective, and patient friendly** [7380-227]
H. C. de Vijlder, T. A. Middelburg, H. S. de Bruijn, D. J. Robinson, H. A. M. Neumann, E. R. M. de Haas, Erasmus Medical Ctr. (Netherlands)
- 7380 6C **Loss of intercellular adhesion leads to differential accumulation of hypericin in bladder cancer** [7380-229]
S. S. Lucky, R. Bhuvaneswari, W. W. L. Chin, National Cancer Ctr. Singapore (Singapore); W. K. O. Lau, Singapore General Hospital (Singapore); M. C. D. Olivo, National Cancer Ctr. Singapore (Singapore), National Univ. of Singapore (Singapore), and Singapore Bioimaging Consortium (Singapore)
- 7380 6D **Combination of angiogenesis inhibitors increases the anti-tumor efficacy of photodynamic therapy in a human bladder tumor xenograft model** [7380-230]
R. Bhuvaneswari, National Cancer Ctr. Singapore (Singapore); Y. Y. Gan, Nanyang Technological Univ. (Singapore); P. S. P. Thong, W. W. L. Chin, K. C. Soo, National Cancer Ctr. Singapore (Singapore); M. Olivo, National Cancer Ctr. Singapore (Singapore), Biomedical Sciences Institutes (Singapore), and National Univ. of Singapore (Singapore)
- 7380 6E **Multiplex infectious disease microarrays: STAT serology on a drop of blood** [7380-231]
T. Ewart, M. Tarnopolsky, S. Baker, S. Raha, McMaster Univ. Medical Ctr. (Canada); Y.-Y. Wong, K. Ciebiera, Xceed Molecular (Canada)
- 7380 6H **A new paradigm for photodynamic therapy: coherent control** [7380-234]
D. Yang, J. Savolainen, A. Jafarpour, D. Sprünken, J. L. Herek, Univ. of Twente (Netherlands)

- 7380 6J **Effect of verteporfin-PDT on the Notch signaling pathway in cholangiocarcinoma (CCA) cell lines** [7380-236]
V. Cerec, F. Andreola, S. P. Pereira, Univ. College London (United Kingdom)
- 7380 6K **Development of novel bifunctional agents with and without tumor imaging ability** [7380-237]
M. Ethirajan, M. Williams, N. Angelino, J. R. Missert, R. K. Pandey, Roswell Park Cancer Institute (United States)
- 7380 6N **In vitro and in vivo studies of new photoluminescent oxygen sensors for non-invasive intravascular pO₂ measurements** [7380-243]
P. Nowak-Sliwinska, E. Forte, H. van den Bergh, G. Wagnières, Swiss Federal Institute of Technology (Switzerland)
- 7380 6P **Effect of verteporfin-PDT on epithelial growth factor receptor (EGFR) signaling pathway in cholangiocarcinoma cell lines** [7380-246]
F. Andreola, V. Cerec, S. P. Pereira, Univ. College London (United Kingdom)
- 7380 6Q **Catheter-based complex swept source optical coherence tomography for biomedical imaging** [7380-247]
Y. Mao, C. Flueraru, S. Chang, National Research Council Canada (Canada)
- 7380 6R **Exploiting bacterial drug resistance: a single construct for the diagnosis and treatment of drug resistant infections (Best Poster Award)** [7380-249]
U. W. Sallum, X. Zheng, S. Verma, T. Hasan, Wellman Ctr. for Photomedicine, MGH (United States) and Harvard Medical School (United States)
- 7380 6U **Detection and diagnosis of human oral cancer using hypericin fluorescence endoscopic imaging interfaced with embedded computing** [7380-252]
P. S. P. Thong, National Cancer Ctr. of Singapore (Singapore); M. Olivo, National Cancer Ctr. of Singapore (Singapore) and Singapore Bioimaging Consortium (Singapore); F. Lin, H.-S. Seah, S. S. Tandjung, K. Qian, Nanyang Technological Univ. (Singapore); W. W. L. Chin, R. Bhuvaneshwari, National Cancer Ctr. of Singapore (Singapore); K. Mancor, Changi General Hospital (Singapore); K.-C. Soo, National Cancer Ctr. of Singapore (Singapore) and Singapore General Hospital (Singapore)
- 7380 6V **Immediate and long-term efficacy and safety of photodynamic therapy with Photolon (Fotolon): a seven-year clinical experience (Best Poster Award)** [7380-253]
Y. P. Istomin, N.N. Alexandrov National Cancer Ctr. of Belarus (Belarus); M. A. Kaplan, Medical Radiology Research Ctr. (Russian Federation); S. V. Shliakhtsin, RUE Belmedpreparaty (Belarus); T. P. Lapzevich, D. A. Cerkovsky, N.N. Alexandrov National Cancer Ctr. of Belarus (Belarus); L. N. Marchanka, A. S. Fedulov, Byelorussian State Medical Univ. (Belarus); T. V. Trukhachova, RUE Belmedpreparaty (Belarus)
- 7380 6W **A Monte Carlo model of detected singlet oxygen luminescence and photosensitizer fluorescence during ALA-PDT of skin** [7380-255]
B. Liu, T. J. Farrell, M. S. Patterson, McMaster Univ. (Canada) and Juravinski Cancer Ctr. (Canada); M. T. Jarvi, B. C. Wilson, Ontario Cancer Institute (Canada) and Univ. of Toronto (Canada)

- 7380 6Y **Molecular mechanisms associated with ALA-PDT of brain tumor cells (Best Poster Award)**
[7380-257]
O. Alqawi, M. Espiritu, G. Singh, McMaster Univ. (Canada)
- 7380 71 **Potential of ALA-PDT antitumor activity in mice using topical DMXAA** [7380-264]
A. Marrero, U. Sunar, T. Sands, A. Oseroff, D. Bellnier, Roswell Park Cancer Institute (United States)
- 7380 72 **Generation of singlet oxygen and other radical species by quantum dot and carbon dot nanosensitizers** [7380-265]
R. Generalov, I. L. Christensen, Oslo Univ. Hospital (Norway) and Univ. of Oslo (Norway);
W. Chen, The Univ. of Texas at Arlington (United States); Y.-P. Sun, Clemson Univ. (United States); S. Kristensen, Univ. of Oslo (Norway); P. Juzenas, Oslo Univ. Hospital (Norway)

Author Index

Conference Committee

Symposium Chair

David H. Kessel, Wayne State University (United States)

Conference Chair

David H. Kessel, Wayne State University (United States)

Organizing Committee

David H. Kessel, Wayne State University (United States)

Tayyaba Hasan, Wellman Center for Photomedicine, Massachusetts
General Hospital (United States)

Charles J. Gomer, Childrens Hospital Los Angeles (United States)

Kenneth K. Wang, Mayo Clinic (United States)

Scientific Advisors

Ahn Woong Schick, Catholic University of Korea (Korea, Republic of)

Xiu-Li Wang, Shanghai Skin Diseases and STD Hospital (China)

Kristian Berg, The Norwegian Radium Hospital, Rikshospitalet University
Hospital (Norway)

Stanley B. Brown, University of Leeds (United Kingdom)

Herwig Kostron, Universität Innsbruck (Austria)

Harubumi Kato, Tokyo Medical University Hospital (Japan)

Session Chairs

Plenary Papers

David H. Kessel, Wayne State University (United States)

- 1 PDT Mechanisms of Phototoxicity
Kristian Berg, The Norwegian Radium Hospital, Rikshospitalet University
Hospital (Norway)
- 2 PDT and Immune Responses I
Mladen Korbelik, British Columbia Cancer Agency (Canada)
- 3 PDT and Immune Responses II
Mladen Korbelik, British Columbia Cancer Agency (Canada)
- 4 PDT: Some of the Variables
Stuart L. Marcus, DUSA Pharmaceuticals, Inc. (United States)

- 5 Clinical PDT I
Stephen Pereira, University College London (United Kingdom)
- 6 Clinical PDT II
Keith A. Cengel, University of Pennsylvania (United States)
- 7 Photocure Workshop on PDT and PD with Porphyrin Precursors
Qian Peng, The Norwegian Radium Hospital, Rikshospitalet University Hospital (Norway)
- 8 Workshop II
Alexander J. MacRobert, University College London (United Kingdom)
- 9 Workshop III
Rolf-Markus Szeimies, University Clinics Regensburg (Germany)
- 10 Workshop IV
Steen J. Madsen, University of Nevada, Las Vegas (United States)
- 11 Preclinical I
Josephine H. Woodhams, University College London (United Kingdom)
- 12 Preclinical II
Colin Hopper, University College London Hospitals NHS Foundation Trust (United Kingdom)
- 13 Clinical PDT III
Merrill A. Biel, University of Minnesota (United States)
- 14 Clinical PDT IV
Ron R. Allison, East Carolina University (United States)
- 15 Clinical PDT V
Edward V. Maytin, Cleveland Clinic Lerner Research Institute (United States)
- 16 PDT Photophysics
Kimberley S. Samkoe, Dartmouth College (United States)
- 17 PDT Mechanisms
Alison Curnow, Cornwall Dermatology Research (United Kingdom)
- 18 PDT Techniques
Sarika Verma, Wellman Center for Photomedicine, Massachusetts General Hospital (United States)

- 19 Sensitizer Synthesis I
Ravindra K. Pandey, Roswell Park Cancer Institute (United States)
Johan E. van Lier, Université de Sherbrooke (Canada)
- 20 Sensitizer Synthesis II
Ravindra K. Pandey, Roswell Park Cancer Institute (United States)
Johan E. van Lier, Université de Sherbrooke (Canada)
- 21 PDT Biophysics and Nanotech
Ozzy Mermut, INO (Canada)
- 22 Clinical PDT VI
Pawel A. Mroz, Massachusetts General Hospital (United States)
- 23 Clinical PDT VII
Ann Johansson, Ludwig-Maximilians-Universität München (Germany)
- 24 Clinical PDT VIII
Sam Eljamel, Ninewells Hospital and Medical School, University of
Dundee (United Kingdom)
- 25 Antimicrobial PDT I
Michael R. Hamblin, Massachusetts General Hospital (United States)
- 26 Antimicrobial PDT II
Giulio Jori, Università degli Studi di Padova (Italy)
- 27 Antimicrobial PDT III
Stanley B. Brown, University of Leeds (United Kingdom)
- 28 Antimicrobial PDT IV
Tim Maisch, University Clinics Regensburg (Germany)
- 29 PDT Dosimetry
Anna-Liisa Nieminen, Medical University of South Carolina
(United States)
- 30 PDT Evaluation Techniques
Theresa M. Busch, The University of Pennsylvania Health System
(United States)
- 31 PDT New Approaches
Seonkyung Lee, Physical Sciences Inc. (United States)
- 32 PDT Targeting
Thierry J. Patrice, Centre Hospitalier Universitaire de Nantes (France)

- 33 PDT Biophysics I
Cale N. Street, Ondine Research Laboratory, Inc. (United States)

- 34 PDT Biophysics II
Jarod C. Finlay, University of Pennsylvania (United States)

- 35 Preclinical PDT Methodology I
Linda R. Jones, College of Charleston (United States)

- 36 Preclinical PDT Methodology II
Thomas H. Foster, University of Rochester Medical Center
(United States)